Access to Medicines Index

Access to Medicines Index
Name	Access to Medicines Index
Formation	2008
Type	Nonprofit research initiative
Headquarters	London
Region served	Global

Access to Medicines Index is an independent benchmark that evaluates how pharmaceutical and biotechnology companies contribute to improving access to medicines in low- and middle-income countries. The index compares corporate performance across transparency, R&D, pricing, and distribution, providing data for civil society, investors, and multilateral bodies to influence corporate behavior and public health outcomes. Its reports inform debates involving stakeholders such as World Health Organization, Bill & Melinda Gates Foundation, World Bank, United Nations, and industry actors including GlaxoSmithKline, Pfizer, Novartis, and Johnson & Johnson.

Overview

The Index ranks multinational pharmaceutical and biotechnology firms by measuring policies, practices, and commitments related to access to medicine across product development, equitable pricing, licensing, and supply-chain strategies. It is used by advocacy organizations like Médecins Sans Frontières, investor coalitions such as Principles for Responsible Investment, and academic centers including London School of Hygiene & Tropical Medicine and Harvard University to assess corporate contributions to goals promoted by Sustainable Development Goals and initiatives linked to Global Fund and Gavi, the Vaccine Alliance. The Index frames corporate responsibility in relation to public health crises such as HIV/AIDS epidemic, Ebola virus epidemic in West Africa, COVID-19 pandemic, and neglected tropical disease programs championed by Bill & Melinda Gates Foundation.

Methodology

The Index uses a weighted indicator framework combining qualitative document analysis, quantitative data collection, and stakeholder interviews to score companies across domains including research and development, patent pooling, pricing strategies, and product delivery. It draws on standards and instruments such as World Health Organization guidance, licensing models like Medicines Patent Pool, and voluntary mechanisms exemplified by Patent Pooling initiatives. Data sources include corporate reports, regulatory filings to agencies like European Medicines Agency and U.S. Food and Drug Administration, and patient-access programs tied to institutions such as Clinton Health Access Initiative and UNITAID. Independent external reviewers and expert panels with representation from Wellcome Trust and university researchers validate findings.

Rankings and Results

Published triennially, the Index produces company rankings and thematic analyses, highlighting leaders and laggards among major firms including Roche, AstraZeneca, Bristol Myers Squibb, Sanofi, and Merck & Co.. Results detail scores for subdomains like equitable pricing, where comparisons reference price-setting precedents from cases involving Gilead Sciences and antiretroviral access programs tied to UNAIDS. Reports have spotlighted company approaches to licensing, mentioning mechanisms used by Bayer and collaborations with organizations such as PATH and Doctors Without Borders. Aggregate findings feed into investor engagement through groups like Ceres and inform procurement dialogues with multilateral purchasers such as UNICEF and Pan American Health Organization.

Impact and Criticism

The Index has influenced corporate policy adjustments, licensing deals, and product donation programs by firms responding to scrutiny from stakeholders including Oxfam, Amnesty International, and institutional investors such as Norwegian Ministry of Finance. It has been cited in policy discussions at forums like World Economic Forum and in analyses by think tanks such as Chatham House and Brookings Institution. Critics argue the Index may privilege transparency over on-the-ground delivery, echoing critiques raised by scholars at University of Oxford and Johns Hopkins Bloomberg School of Public Health, and point to limitations similar to debates around Corporate Social Responsibility measurement and accountability mechanisms discussed in literature involving Transparency International and Human Rights Watch.

History and Development

Conceived amid debates about pharmaceutical ethics and access in the early 21st century, the Index was created to synthesize corporate accountability data following high-profile campaigns around access to antiretrovirals and drug pricing controversies involving entities such as MSF (Doctors Without Borders) and public health advocates associated with Treatment Action Campaign. Early iterations reflected influence from philanthropies like Gates Foundation and global health financiers such as UNITAID and the Global Fund to Fight AIDS, Tuberculosis and Malaria. Over successive editions, methodological refinements incorporated input from academics at Imperial College London and practitioners with experience at World Health Organization and World Bank programs.

Governance and Funding

The Index is governed by an independent secretariat and advisory panels composed of experts from academia, civil society, philanthropy, and investor communities, with oversight mechanisms designed to uphold impartiality comparable to governance structures seen at institutions like International Committee of the Red Cross and advisory boards of Wellcome Trust. Funding has come from a mixture of philanthropic donors, multilateral agencies, and foundations, with notable supporters including Bill & Melinda Gates Foundation, Wellcome Trust, and multilateral initiatives such as UNITAID. Editorial independence is maintained through conflict-of-interest policies and external peer review involving scholars from London School of Economics and practitioners from Clinton Health Access Initiative.

Category:Global health